|Day Low/High||15.26 / 15.70|
|52 Wk Low/High||10.51 / 21.00|
Trade-Ideas LLC identified Vericel (VCEL) as a strong on high relative volume candidate
Trade-Ideas LLC identified Vericel (VCEL) as a weak on high relative volume candidate
Patients Treated with Ixmyelocel-T had a 37 Percent Reduction in Clinical Events Compared to Placebo
Key Opinion Leader to present full data results on April 5th in New York
Investors in Vericel Corp saw new options become available this week, for the May 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the VCEL options chain for the new May 20th contracts and identified one put and one call contract of particular interest.
Vericel (VCEL) stock is dipping on Monday morning after the biopharmaceutical company posted lower-than-expected results for the 2015 fourth quarter before today’s opening bell.
Trade-Ideas LLC identified Vericel (VCEL) as a pre-market mover with heavy volume candidate
Vericel (VCEL) stock is surging in mid-morning trading Thursday after the company reported positive results from its Phase 2 trial for patients with heart failure due to ischemic dilated cardiomyopathy.
Study Meets Primary Endpoint of Reduction in Clinical Cardiac Events
Revised Product Label Includes Indication for Use in Pediatric Patients and Now Specifies a Probable Benefit of Epicel Mainly Related to Patient Survival
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.